LJPC..has two orphan drug designations. Fibroplasia ossificans progressiva and Niemann-Pick type C disease.
La Jolla Pharmaceutical Company Receives Orphan Designation from FDA for LJPC-6417 | La Jolla Pharmaceutical http://bit.ly/JZwiHx (APRIL 18th, 2013) FDA Office of Orphan Products Development has granted an “Orphan Drug” designation to La Jolla’s drug candidate LJPC-6417 for fibrodysplasia ossificans progressiva (“FOP”), more commonly known as “Stone Man Disease.”
La Jolla Pharmaceutical Company Receives Orphan Designation From FDA - Yahoo Finance http://yhoo.it/1e8yGVO (July 17th). FDA Office of Orphan Products Development has granted an "Orphan Drug" designation to La Jolla's drug candidate LJPC-0712 for treatment of Niemann-Pick type C disease.
Market Data 
Markets 
AI
